Phase 3 Lung Cancer Trial, Recruiting (NCT05055908)

Phase 3 Lung Cancer Trial, Recruiting NCT05055908 Sponsor: Hunan Province Tumor Hospital Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05055908 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who understand what the trial involves and have signed and dated a consent form agreeing to take part.
People aged 18 or older.
People whose lung cancer has been confirmed through laboratory testing of tissue or cell samples.
People who have previously been treated with immune checkpoint inhibitor therapy, with or without chemotherapy.
People whose doctors estimate they are likely to survive for at least 12 weeks.
People whose bone marrow, blood counts, and organ function are at adequate levels (confirm with trial site).
People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines (confirm with trial site).

Who may not be able to join:

People who do not meet any of the inclusion criteria listed above.
People for whom there is not enough medical data available to assess and record any side effects or harmful reactions during the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital

Phone: +8613873123436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05055908

Sponsor: Hunan Province Tumor Hospital

Phase: Phase 3

Status: Recruiting

Condition: Lung Cancer

Trial contact: +8613873123436

More information: https://clinicaltrials.gov/study/NCT05055908

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who understand what the trial involves and have signed and dated a consent form agreeing to take part.
People aged 18 or older.
People whose lung cancer has been confirmed through laboratory testing of tissue or cell samples.
People who have previously been treated with immune checkpoint inhibitor therapy, with or without chemotherapy.
People whose doctors estimate they are likely to survive for at least 12 weeks.
People whose bone marrow, blood counts, and organ function are at adequate levels (confirm with trial site).
People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines (confirm with trial site).

Who may not be able to join:

People who do not meet any of the inclusion criteria listed above.
People for whom there is not enough medical data available to assess and record any side effects or harmful reactions during the trial.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Hunan Province Tumor Hospital

Registry

ClinicalTrials.gov

Start date

1 October 2021

Est. completion

1 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Correlation between Adverse events (AEs) and gene profile

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov